Who is sponsoring NCT01416974?

NCT01416974 is sponsored by Memorial Sloan Kettering Cancer Center.

What drugs are being tested in NCT01416974?

Interventions: cyclophosphamide, modified T cells.

What is the status of NCT01416974?

NCT01416974 is currently COMPLETED.

Last reviewed 2019-01-11 · How we verify

Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab

NCT01416974 PHASE1 COMPLETED

The purpose of this Phase I study is to test the safety and effect of specially prepared cells collected from the patients called "modified T cells." We want to find a safe dose of modified T cells for patients who have disease remaining after initial chemotherapy. We also want to find out what effects these T cells have on you and your leukemia.

Details

Lead sponsor	Memorial Sloan Kettering Cancer Center
Phase	PHASE1
Status	COMPLETED
Enrolment	13
Start date	Mon Aug 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Jan 07 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Leukemia

Interventions

cyclophosphamide
modified T cells

Countries

United States